Dermatologicals
Refine Search
Pharmaceutical
Privately-held Danish dermatology specialist LEO Pharma today revealed that the US Food and Drug Administration (FDA) has approved Anzupgo (delgocitinib) cream (20 mg/g) for the topical treatment of moderate-to-severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable. 24 July 2025
Biotechnology
Scancell Holdings, the developer of Immunobody and Moditope active immunotherapies to treat cancer, has announced further positive data from the ongoing Phase II SCOPE trial of SCIB1/iSCIB1+ Immunobody DNA active immunotherapies in combination with checkpoint inhibitors in advanced unresectable melanoma. 23 July 2025
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis, submitted by US pharma major Bristol Myers Squibb. 21 July 2025
Biotechnology
Indian pharma major Sun Pharma reported positive top-line results from two late-stage studies of its psoriasis drug Ilumya (tildrakizumab), showing it helped reduce joint inflammation in people with active psoriatic arthritis. 21 July 2025
Pharmaceutical
Indian drugmaker Sun Pharmaceutical Industries together with its subsidiaries announced that further to its intimation dated April 10, 2025, Sun and Incyte Corporation have entered into a settlement and license agreement regarding litigation related to Leqselvi (deuruxolitinib). 15 July 2025
Biotechnology
German family-owned pharma major Boehringer Ingelheim and Denmark’s LEO Pharma today announced an exclusive global license and transfer agreement to commercialize and advance the development of Spevigo (spesolimab). 14 July 2025
Pharmaceutical
A new analysis from US data analytics firm Phesi has raised concerns about the viability of ongoing Phase III trials in atopic dermatitis (AD), pointing to a rising risk of failure driven by flawed trial design and overreliance on saturated investigator sites. 9 July 2025
Biotechnology
Shares of US clinical-stage biotech Apogee Therapeutic closed down 17.3% at $39.24 yesterday, despite announcing positive 16-week data from Part A of the Phase II APEX clinical trial of APG777, a potential best-in-class anti-interleukin (IL)-13 antibody, in patients with moderate-to-severe atopic dermatitis (AD). 8 July 2025
Biotechnology
Italian drugmaker Philogen has announced its decision to voluntarily withdraw the application for marketing authorization to the European Medicines Agency (EMA) for Nidlegy(daromun), a biological investigational medicinal product which is intended to be used for the neoadjuvant treatment of adult patients with locally advanced fully resectable melanoma. 27 June 2025
Biotechnology
US biotech Nektar Therapeutics experienced a remarkable 130% increase in its share price, which reached $21.9, as it reported the successful outcome of a study related to atopic dermatitis. 24 June 2025
Biotechnology
New York-based Formation Bio, an AI-native pharma company focused on accelerating drug development, revealed that its subsidiary Libertas Bio has licensed gusacitinib to Sanofi, expanding the partnership between the companies. 24 June 2025
Biotechnology
Further expanding the indications for French pharma major Sanofi’s mega-blockbuster Dupixent (dupilumab), the US Food and Drug Administration (FDA) has approved the drug for the treatment of adult patients with bullous pemphigoid (BP). 20 June 2025
Biotechnology
Spanish skincare specialist Almirall has promised a key contribution at the International Congress of Dermatology (ICD), currently taking place in Rome, Italy. 19 June 2025
Biotechnology
The UK’s National Institute for Health and Care Excellence (NICE) has today recommended Spevigo (spesolimab) for the treatment of generalized pustular psoriasis (GPP) flares in adults in England and Wales. 18 June 2025
Biotechnology
Californian biotech Jasper Therapeutics presented data from the 180mg cohort of the company’s SPOTLIGHT Phase Ib/IIa study of subcutaneous briquilimab in adult participants with chronic inducible urticaria (CIndU) at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress. 16 June 2025
Biotechnology
US immunology specialist Celldex was trading 5% higher midday Friday, following on from 10% gains on Thursday. 13 June 2025
Biosimilars
South Korea’s biosimilar drug developer Samsung Bioepis has announced that the company has entered into a license, development and commercialization agreement with Nipro Corporation for multiple biosimilar candidates including SB17, a ustekinumab biosimilar candidate, in Japan. 9 June 2025
Biotechnology
Swiss skincare specialist Galderma has announced two-year data from a new interim analysis of a long-term extension study investigating the safety and efficacy of Nemluvio (nemolizumab) in moderate-to-severe atopic dermatitis (AD). 9 June 2025
Biotechnology
US biotech Regeneron Pharmaceuticals and French pharma major Sanofi on Saturday presented results from the DISCOVER Phase IV, single-arm, open-label trial assessing Dupixent (dupilumab) in adults and adolescents with moderate-to-severe atopic dermatitis with skin of color. 9 June 2025
Pharmaceutical
The atopic dermatitis market across the seven major markets is forecast to nearly triple in value over the next decade, driven by advances in targeted therapies and a deeper understanding of disease mechanisms. 5 June 2025
Pharmaceutical
Privately-held Danish dermatology specialist LEO Pharma today revealed that the US Food and Drug Administration (FDA) has approved Anzupgo (delgocitinib) cream (20 mg/g) for the topical treatment of moderate-to-severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable. 24 July 2025
Biotechnology
Scancell Holdings, the developer of Immunobody and Moditope active immunotherapies to treat cancer, has announced further positive data from the ongoing Phase II SCOPE trial of SCIB1/iSCIB1+ Immunobody DNA active immunotherapies in combination with checkpoint inhibitors in advanced unresectable melanoma. 23 July 2025
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis, submitted by US pharma major Bristol Myers Squibb. 21 July 2025
Biotechnology
Indian pharma major Sun Pharma reported positive top-line results from two late-stage studies of its psoriasis drug Ilumya (tildrakizumab), showing it helped reduce joint inflammation in people with active psoriatic arthritis. 21 July 2025
Pharmaceutical
Indian drugmaker Sun Pharmaceutical Industries together with its subsidiaries announced that further to its intimation dated April 10, 2025, Sun and Incyte Corporation have entered into a settlement and license agreement regarding litigation related to Leqselvi (deuruxolitinib). 15 July 2025
Biotechnology
German family-owned pharma major Boehringer Ingelheim and Denmark’s LEO Pharma today announced an exclusive global license and transfer agreement to commercialize and advance the development of Spevigo (spesolimab). 14 July 2025
Pharmaceutical
A new analysis from US data analytics firm Phesi has raised concerns about the viability of ongoing Phase III trials in atopic dermatitis (AD), pointing to a rising risk of failure driven by flawed trial design and overreliance on saturated investigator sites. 9 July 2025
Biotechnology
Shares of US clinical-stage biotech Apogee Therapeutic closed down 17.3% at $39.24 yesterday, despite announcing positive 16-week data from Part A of the Phase II APEX clinical trial of APG777, a potential best-in-class anti-interleukin (IL)-13 antibody, in patients with moderate-to-severe atopic dermatitis (AD). 8 July 2025
Biotechnology
Italian drugmaker Philogen has announced its decision to voluntarily withdraw the application for marketing authorization to the European Medicines Agency (EMA) for Nidlegy(daromun), a biological investigational medicinal product which is intended to be used for the neoadjuvant treatment of adult patients with locally advanced fully resectable melanoma. 27 June 2025
Biotechnology
US biotech Nektar Therapeutics experienced a remarkable 130% increase in its share price, which reached $21.9, as it reported the successful outcome of a study related to atopic dermatitis. 24 June 2025
Biotechnology
New York-based Formation Bio, an AI-native pharma company focused on accelerating drug development, revealed that its subsidiary Libertas Bio has licensed gusacitinib to Sanofi, expanding the partnership between the companies. 24 June 2025
Biotechnology
Further expanding the indications for French pharma major Sanofi’s mega-blockbuster Dupixent (dupilumab), the US Food and Drug Administration (FDA) has approved the drug for the treatment of adult patients with bullous pemphigoid (BP). 20 June 2025
Biotechnology
Spanish skincare specialist Almirall has promised a key contribution at the International Congress of Dermatology (ICD), currently taking place in Rome, Italy. 19 June 2025
Biotechnology
The UK’s National Institute for Health and Care Excellence (NICE) has today recommended Spevigo (spesolimab) for the treatment of generalized pustular psoriasis (GPP) flares in adults in England and Wales. 18 June 2025
Biotechnology
Californian biotech Jasper Therapeutics presented data from the 180mg cohort of the company’s SPOTLIGHT Phase Ib/IIa study of subcutaneous briquilimab in adult participants with chronic inducible urticaria (CIndU) at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress. 16 June 2025
Biotechnology
US immunology specialist Celldex was trading 5% higher midday Friday, following on from 10% gains on Thursday. 13 June 2025
Biosimilars
South Korea’s biosimilar drug developer Samsung Bioepis has announced that the company has entered into a license, development and commercialization agreement with Nipro Corporation for multiple biosimilar candidates including SB17, a ustekinumab biosimilar candidate, in Japan. 9 June 2025
Biotechnology
Swiss skincare specialist Galderma has announced two-year data from a new interim analysis of a long-term extension study investigating the safety and efficacy of Nemluvio (nemolizumab) in moderate-to-severe atopic dermatitis (AD). 9 June 2025
Biotechnology
US biotech Regeneron Pharmaceuticals and French pharma major Sanofi on Saturday presented results from the DISCOVER Phase IV, single-arm, open-label trial assessing Dupixent (dupilumab) in adults and adolescents with moderate-to-severe atopic dermatitis with skin of color. 9 June 2025
Pharmaceutical
The atopic dermatitis market across the seven major markets is forecast to nearly triple in value over the next decade, driven by advances in targeted therapies and a deeper understanding of disease mechanisms. 5 June 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze